April W Armstrong MD MPH

0:01:09

Oral Psoriasis Therapy: What's New. April W. Armstrong, MD, MPH

0:01:31

April W Armstrong, MD, MPH

0:01:23

April Armstrong, MD, MPH - What is your favorite biologic in geriatric patients?

0:00:57

April Armstrong, MD, MPH - How do you manage patients on biologics who have orthopedic surgery?

0:02:34

FC21 - What's New in JAMA Dermatology, April W. Armstrong, MD, MPH

0:03:22

FC21 - IL-17 Blockers, April W. Armstrong, MD, MPH

0:03:12

April Armstrong, MD, MPH - How do you decide whether to use a JAK first line vs monoclonal antibody?

0:01:44

April Armstrong, MD, MPH - How do you transition psoriasis patients from methotrexate to a biologic?

0:00:32

April Armstrong MD, MPH - How does dupilimab affect scheduled live pediatric vaccines?

0:00:49

April Armstrong, MD, MPH - What is your favorite biologic in those with treated latent TB?

0:01:45

April Armstrong, MD, MPH - How do you manage patients who develop candidiasis while on IL-17?

0:03:25

2022 Commit to Cure Gala: Celebrating Women Who Lead - April Armstrong, M.D., MPH

0:14:53

Updates on Topical Treatments for Inflammatory Skin Diseases

0:01:00

April Armstrong, MD, MPH - How do I transition from cyclosporine to dupilumab for patients with AD?

0:02:07

April Armstrong, MD, MPH - How do you manage the diarrhea associated with apremilast?

0:01:03

April Armstrong, MD, MPH - Concerns w/ use of IL-23 or IL-17 inhibitors in patients w/ cSCC history?

0:02:48

April Armstrong, MD, MPH - How do you manage conjunctivitis that occurs while on dupilumab?

0:01:18

IL-23 Therapies in the Management of Psoriasis: Alice Gottlieb, MD, PhD & April W Armstrong, MD, MPH

0:14:45

Trials and Tribulations: Clinical Trials in Dermatology

0:02:32

How do you explain the difference between the JAK and TYK2 MOAs?

0:02:01

April Armstrong, MD, MPH - How long should you hold dupilumab prior to live vaccine injection?

0:16:21

Don’t Overlook PsA

0:01:28

How Can I Efficiently Screen for PsA in the Clinic

0:01:44

Psoriasis Update 3: Challenges for the HCP